Adult Subjects With Uncontrolled Type 2 Diabetes
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 149 participants.
Also called NCT02317796
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 149 participants
- Sponsor
- Melior Pharmaceuticals
- Registry
-
NCT02317796
-
- Other papers using this trial's data
- A novel non-PPARgamma insulin sensitizer: MLR-1023 clinicalproof-of-concept in type 2 diabetes mellitus
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT02317796. Randomized; triple masking; primary purpose treatment. Start 2014-12 (registry gives no type); primary completion 2015-12 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Adult Subjects With Uncontrolled Type 2 Diabetes
- Condition
- Type 2 Diabetes
- Intervention (Drug)
- MLR-1023
- Lead sponsor
- Melior Pharmaceuticals
- Collaborator
- Bukwang Pharmaceutical, Co., Ltd.
Record details
- Record id
cardio:ct-nct02317796- Content hash
13f5211840e8b6324adc83952cff1695ccdcf0553dc02c2c6703812793c76cd8